Navigation Links
Lexicon Initiates Phase 2 Clinical Trial of LX2931 in Patients With Rheumatoid Arthritis
Date:8/4/2009

THE WOODLANDS, Texas, Aug. 4 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a Phase 2 clinical trial of LX2931 in patients with rheumatoid arthritis. LX2931 is an orally-delivered, small molecule drug candidate that has recently completed Phase 1 testing in normal volunteers. Lexicon also successfully completed a drug-drug interaction (DDI) study of LX2931 with methotrexate in patients with rheumatoid arthritis, with no clinically significant drug-drug interactions observed.

"We believe that, as an oral therapy, LX2931 could have advantages over current biologic therapies in treating patients with rheumatoid arthritis," said Philip M. Brown, M.D., J.D., senior vice president of clinical development at Lexicon. "LX2931 has demonstrated potent anti-inflammatory activity in preclinical models of arthritis and inflammation and, importantly, has been well tolerated in combination with methotrexate, the current standard of care first-line therapy."

LX2931 inhibits sphingosine-1-phosphate (S1P) lyase, an enzyme identified by Lexicon scientists as a promising new target on a pathway associated with regulation of the human immune system. Lexicon has previously shown that genetically "knocking out" or "knocking down" S1P lyase in mice substantially decr
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results
2. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
3. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
4. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
5. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
6. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
7. Harbinger Research Initiates Coverage on HearAtLast
8. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
9. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
10. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
11. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... ... September 04, 2015 , ... According to an article published September ... in nursing homes and assisted living facilities are receiving insufficient care that could actually ... her father was at one point close to death, not because of a medical ...
(Date:9/4/2015)... ... 2015 , ... On the heels of highly successful events ... its annual health tech innovation program. Now featuring a two-phase health tech competition ... cash and prizes to advance their technologies toward commercialization, the newly expanded program ...
(Date:9/4/2015)... ... September 04, 2015 , ... The Schmidt National Law Group filed an ... , Schmidt National Law Group, a leading firm in mass-tort litigation, has filed ... Corp., Bayer Essure, Inc., and other Bayer affiliates for injuries alleged to have been ...
(Date:9/4/2015)... GA (PRWEB) , ... September 04, 2015 , ... ... Bogart and the surrounding communities, is launching a charity effort to provide for ... Commonly referred to as an enlarged heart, restrictive cardiomyopathy often leads to diastolic ...
(Date:9/4/2015)... ... September 04, 2015 , ... A ... Compassion Project. Core Compassion Project is a non-profit organization dedicated to offering ... side effects of cancer treatments and recover their mobility, strength, and range of ...
Breaking Medicine News(10 mins):Health News:Op-Ed about Insufficient Care for Elderly Patients Highlights the Advantages of Quality, At-Home Care, says Dr. Michael Farzam 2Health News:Op-Ed about Insufficient Care for Elderly Patients Highlights the Advantages of Quality, At-Home Care, says Dr. Michael Farzam 3Health News:Insight Product Development Startup Competition on Track to Double Program Impact 2Health News:Insight Product Development Startup Competition on Track to Double Program Impact 3Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 3Health News:Girl’s Night Out to Benefit Core Compassion Project, Located at the Beautiful, Morning Glory Farm 2
... Interferon does not slow or halt the progression of ... who havent responded to previous attempts to eradicate the ... University School of Medicine participated has found. , Patients ... experience a significant decrease in viral levels and liver ...
... spinal manipulation , , FRIDAY, Nov. 9 (HealthDay News) ... back pain -- nonsteroidal anti-inflammatory drugs (NSAIDs) and ... a carefully controlled study, Australian researchers report. , ... the evidence for their effectiveness has never been ...
... RURL ) announced it will release results for the ... 2007 fourth quarter,and 12 months ended June 30, 2007 ... conjunction, the Company will host a conference call and,webcast ... 11 a.m.,(Eastern). Also on that day, the Company ...
... non-recurring event in 2007, net loss stable ... unless otherwise noted), BELLEVILLE, ON, Nov. 9 /PRNewswire-FirstCall/ ... Canadian,biopharmaceutical company, today announced financial results for the first,quarter ... "We are also focused on the successful completion ...
... Treat One of the ... World,s Oldest and Deadliest Diseases, CAPE TOWN, South Africa, ... Against Tuberculosis and Lung,Disease (IUATLD), The Lilly MDR-TB Partnership brought ... Africa as a model for the work being done by ...
... Cash Technologies, Inc.,(Amex: TQ ) ("Cash Tech" ... (the "Exchange" or "AMEX") notified Cash Tech on November ... the Exchange,s continued,listing standards as set forth in part ... Cash Tech is not in compliance with Section,1003(a)(i) of ...
Cached Medicine News:Health News:Interferon does not slow or stop hepatitis C from worsening, study finds 2Health News:NSAID Drug Therapy Fails to Ease Back Pain 2Health News:Rural/Metro to Host Conference Call to Discuss Results for First Quarter Fiscal 2008 and Fourth Quarter/Fiscal 2007 Year-End 2Health News:Bioniche Reports Fiscal 2008 First Quarter 2Health News:Bioniche Reports Fiscal 2008 First Quarter 3Health News:Bioniche Reports Fiscal 2008 First Quarter 4Health News:Bioniche Reports Fiscal 2008 First Quarter 5Health News:Bioniche Reports Fiscal 2008 First Quarter 6Health News:Bioniche Reports Fiscal 2008 First Quarter 7Health News:Bioniche Reports Fiscal 2008 First Quarter 8Health News:Bioniche Reports Fiscal 2008 First Quarter 9Health News:Bioniche Reports Fiscal 2008 First Quarter 10Health News:Bioniche Reports Fiscal 2008 First Quarter 11Health News:The Lilly MDR-TB Partnership Provides Unique Model for Fight Against Multidrug-Resistant Tuberculosis in South Africa 2Health News:The Lilly MDR-TB Partnership Provides Unique Model for Fight Against Multidrug-Resistant Tuberculosis in South Africa 3Health News:Cash Technologies Discusses AMEX Listing Requirements 2Health News:Cash Technologies Discusses AMEX Listing Requirements 3Health News:Cash Technologies Discusses AMEX Listing Requirements 4
(Date:9/4/2015)... India , September 4, 2015 ... Market by Application (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) ... Technology and by Product - Global Forecast to 2020", ... to reach USD 2.5 Billion by 2020, growing at ... 2015 to 2020. Browse 139 Tables ...
(Date:9/4/2015)... Future Prospects for Companies in Antihistamines, Corticosteroids, ... - new study showing you trends, partnerships, and ... allergic rhinitis drugs heading? What are the commercial prospects ... you potential revenues and other trends to 2025, discussing ... report provides 273 tables, charts, and graphs. Discover the ...
(Date:9/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/gbd3bt/stability_testing ) ... of Pharmaceuticals (London, UK - December 2-3, 2015)" ... comprehensive two day seminar delegates will: - ... suitable for global arketing - Be able to ... and facilities - Know how to save resource ...
Breaking Medicine Technology:Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Stability Testing of Pharmaceuticals: 2 Day Seminar - London, UK - December 2-3, 2015 2
Versatility of the DFS Standard Fixator provides unsurpassed below-the-ring correction of angular, rotational and translational deformities. Length discrepancy can be precisely corrected in 1/4mm inc...
The PreFix™ temporary fixator prepares you for any situation that requires rapid stabilization of complex fractures....
Angulation, translation and rotation. A whole different point of view. The Sheffield Ring Fixation System is a design achievement that advances the possibilities of fracture management....
For radial/ulnar translation, angulation, dorsal/volar translation, and incremental longitudinal distraction, this advanced system is appropriate when incremental adjustment provides an adjunctive me...
Medicine Products: